This afternoon I am off to the American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco. There has already been some information leaking to the media about some of the presentations that will be going on at the conference. One such “leak” is about findings from Memorial Sloan Kettering Cancer Center [...]
Last year GenomeDx Biosciences presented data showing that its Decipher® Prostate Cancer Classifier (the test), a genomic test, is capable of predicting the probability that a man will eventually develop metastatic prostate cancer, despite having surgery as a primary treatment for prostate cancer. The company claims that the test out performs other existing tests of [...]
I have often had men recently diagnosed with advanced, metastatic prostate cancer call me and ask if surgery makes any sense for them to consider. I have never been sure how to respond given that their cancer is known to be already out of their gland. In response to this common question, researchers from the [...]
Clinical trials have shown that there is an overall survival and radiographic progression-free survival benefit derived from abiraterone acetate (Zytiga) in the treatment of men with metastatic castration resistant prostate cancer (mCRPC). A new retrospective study published online, ahead of print, shows this trend is true regardless of a man's Gleason score at diagnosis, despite [...]
Knowing the negative prognostic factors for successful treatment when you have a a biochemical recurrence (PSA only) of your prostate cancer is important. These factors can help you make your treatment decisions because they assist you in evaluating your possible clinical outcome. In a single institutional review of negative prognostic outcomes of salvage radiotherapy in [...]